文献速递肝病

肝移植后代谢功能障碍相关脂肪性肝病的治疗策略制定路径

Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
PubMed 文献 · Hepatology · 2023-12-13

肝移植后代谢功能障碍相关脂肪性肝病(MASLD)常见,分为复发性与新生性,纤维化进展较非移植人群更快,代谢负担高且与肝病协同影响临床病程。本文提供药物研发指导,纳入移植管理细节以促进肝移植后MASLD的治疗开发。

要点

  • 肝移植后MASLD常见,可分为复发性与新生性两类。
  • 肝移植后MASLD患者纤维化进展加速,肝硬化发生较非移植人群更快。
  • 本文提供肝移植后MASLD治疗研发指导,纳入移植管理细节。

核心结论

  • 本文为肝移植后MASLD的治疗开发提供指导,纳入移植管理细节以促进药物研发。

研究设计与样本

  • 本文为指导性文件,旨在为肝移植后MASLD患者的治疗开发提供路径与监管方法。

主要发现

  • 肝移植后MASLD常见,复发性见于因代谢功能障碍相关脂肪性肝炎(MASH)接受肝移植者,新生性见于因非MASH病因接受肝移植者。
  • 肝移植后MASLD患者纤维化进展加速,肝硬化发生较一般(即非肝移植)人群更快。
  • 肝移植后MASLD患者代谢负担高,并与肝病协同对临床病程产生负面影响。
  • 目前肝移植后MASLD患者群体缺乏监管路径与治疗开发途径。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Occurrence of metabolic dysfunction-associated steatotic liver disease (MASLD) is common following liver transplantation (LT). MASLD can be classified as a recurrent disease when it occurs in patients receiving LT for metabolic dysfunction-associated steatohepatitis (MASH) or as de novo when it occurs in patients undergoing transplantation for non-metabolic dysfunction-associated steatohepatitis etiologies of liver disease. Fibrosis progression in patients with MASLD is accelerated, with progression to cirrhosis occurring more rapidly compared with the general (ie, non-LT) population. Moreover, the metabolic burden in LT recipients with MASLD is high and synergizes with liver disease to negatively affect the clinical course. Despite the oversized clinical burden of MASLD among LT recipients, there is currently a lack of regulatory approach and pathway for therapeutics development in this patient population. The present document, thus, provides guidance for therapeutics development that incorporates nuances of transplant care in patients with post-LT MASLD to facilitate drug development.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Siddiqui MS, Muthiah M, Satapathy SK, et al. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation. Hepatology. 2023. PMID: 38088872. doi:10.1097/HEP.0000000000000720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。